HBV (19) _ Anti-inflammatory and liver-preserving therapy

Liver inflammation and necrosis and the hepatic fibrosis caused by it are the main pathological basis of the progression of disease, so it is possible to reduce the liver cell damage and delay the development of hepatic fibrosis if it can inhibit the inflammation of liver tissue effectively. Glycyrrhizic acid preparation, silymarin and other preparation active ingredients are more clear, there are different degrees of anti-inflammatory, antioxidant, protective liver cell membrane and organelles, such as the role of clinical application of these agents can improve the liver biochemical index (ⅱ-2,ii-3). biphenyl esters and double-cyclohexanol can also reduce serum amino-transferase, especially alt level.

Anti-inflammatory and liver-preserving treatment is only part of the integrated treatment and does not replace antiviral therapy. The anti-inflammatory and liver-preserving drugs can be selected on the basis of antiviral therapy for patients with significant alt-elevation or hepatic histological inflammation necrosis. It is not advisable to apply multiple anti-inflammatory and liver-preserving drugs at the same time to avoid aggravating the burden of liver and causing adverse effects due to drug interactions.

HBV (19) _ Anti-inflammatory and liver-preserving therapy